Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

15 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Author Correction: BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer.
Karachaliou N, Codony-Servat J, Teixidó C, Pilotto S, Drozdowskyj A, Codony-Servat C, Giménez-Capitán A, Molina-Vila MA, Bertrán-Alamillo J, Gervais R, Massuti B, Morán T, Majem M, Felip E, Carcereny E, García-Campelo R, Viteri S, González-Cao M, Morales-Espinosa D, Verlicchi A, Crisetti E, Chaib I, Santarpia M, Luis Ramírez J, Bosch-Barrera J, Felipe Cardona A, de Marinis F, López-Vivanco G, Miguel Sánchez J, Vergnenegre A, Sánchez Hernández JJ, Sperduti I, Bria E, Rosell R. Karachaliou N, et al. Among authors: codony servat c. Sci Rep. 2023 Mar 3;13(1):3620. doi: 10.1038/s41598-023-30374-9. Sci Rep. 2023. PMID: 36869103 Free PMC article. No abstract available.
BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer.
Karachaliou N, Codony-Servat J, Teixidó C, Pilotto S, Drozdowskyj A, Codony-Servat C, Giménez-Capitán A, Molina-Vila MA, Bertrán-Alamillo J, Gervais R, Massuti B, Morán T, Majem M, Felip E, Carcereny E, García-Campelo R, Viteri S, González-Cao M, Morales-Espinosa D, Verlicchi A, Crisetti E, Chaib I, Santarpia M, Luis Ramírez J, Bosch-Barrera J, Felipe Cardona A, de Marinis F, López-Vivanco G, Miguel Sánchez J, Vergnenegre A, Sánchez Hernández JJ, Sperduti I, Bria E, Rosell R. Karachaliou N, et al. Sci Rep. 2015 Dec 7;5:17499. doi: 10.1038/srep17499. Sci Rep. 2015. PMID: 26639561 Free PMC article.
Cancer Stem Cell Biomarkers in EGFR-Mutation-Positive Non-Small-Cell Lung Cancer.
Codony-Servat J, Codony-Servat C, Cardona AF, Giménez-Capitán A, Drozdowskyj A, Berenguer J, Bracht JWP, Ito M, Karachaliou N, Rosell R. Codony-Servat J, et al. Among authors: codony servat c. Clin Lung Cancer. 2019 May;20(3):167-177. doi: 10.1016/j.cllc.2019.02.005. Epub 2019 Feb 21. Clin Lung Cancer. 2019. PMID: 30885551
AURKB as a target in non-small cell lung cancer with acquired resistance to anti-EGFR therapy.
Bertran-Alamillo J, Cattan V, Schoumacher M, Codony-Servat J, Giménez-Capitán A, Cantero F, Burbridge M, Rodríguez S, Teixidó C, Roman R, Castellví J, García-Román S, Codony-Servat C, Viteri S, Cardona AF, Karachaliou N, Rosell R, Molina-Vila MA. Bertran-Alamillo J, et al. Among authors: codony servat c. Nat Commun. 2019 Apr 18;10(1):1812. doi: 10.1038/s41467-019-09734-5. Nat Commun. 2019. PMID: 31000705 Free PMC article.
Hsp90 inhibitors enhance the antitumoral effect of osimertinib in parental and osimertinib-resistant non-small cell lung cancer cell lines.
Codony-Servat J, Viteri S, Codony-Servat C, Ito M, Bracht JWP, Berenguer J, Chaib I, Molina-Vila MA, Karachaliou N, Rosell R. Codony-Servat J, et al. Among authors: codony servat c. Transl Lung Cancer Res. 2019 Aug;8(4):340-351. doi: 10.21037/tlcr.2019.08.22. Transl Lung Cancer Res. 2019. PMID: 31555510 Free PMC article.
Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer.
Jacobsen K, Bertran-Alamillo J, Molina MA, Teixidó C, Karachaliou N, Pedersen MH, Castellví J, Garzón M, Codony-Servat C, Codony-Servat J, Giménez-Capitán A, Drozdowskyj A, Viteri S, Larsen MR, Lassen U, Felip E, Bivona TG, Ditzel HJ, Rosell R. Jacobsen K, et al. Nat Commun. 2017 Sep 4;8(1):410. doi: 10.1038/s41467-017-00450-6. Nat Commun. 2017. PMID: 28871105 Free PMC article.
Inhibition of MEK, a canonical KRAS pathway effector in KRAS mutant NSCLC.
Rosell R, Karachaliou N, Codony-Servat C, Ito M. Rosell R, et al. Among authors: codony servat c. Transl Lung Cancer Res. 2018 Sep;7(Suppl 3):S183-S186. doi: 10.21037/tlcr.2018.03.20. Transl Lung Cancer Res. 2018. PMID: 30393596 Free PMC article. No abstract available.
15 results